Search
Menu
Home
Sources
About
Contacts
Linzagolix
Linzagolix
is a
small-molecule
,
non-peptide
,
orally active
gonadotropin-releasing hormone antagonist
which is
under development
by
Kissei Pharmaceutical
and ObsEva for the
treatment
of
uterine fibroids
,
endometriosis
, and
adenomyosis
. As of
December 2017
, it is
in phase
III
clinical trials
for
uterine
fibroids
and
phase II
clinical studies
for endometriosis and adenomyosis.